LFA
SUPN icon

LGT Financial Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

LGT Financial Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-130
Closed -$4.7K – 675
2024
Q4 		$4.7K Hold
130
– – 0.01% 561
2024
Q3 		$4.05K Hold
130
– – 0.01% 574
2024
Q2 		$3.48K Hold
130
– – 0.01% 655
2024
Q1 		$4.43K Hold
130
– – 0.01% 637
2023
Q4 		$3.76K Hold
130
– – ﹤0.01% 681
2023
Q3 		$3.58K Buy
+130
New +$3.96K ﹤0.01% 693

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

LGT Financial Advisors's SUPN Position: Q1 2025 in Review

LGT Financial Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2025, closing a stake of 130 shares — an estimated $4.7K sold.

LGT Financial Advisors first reported a position in SUPN in Q3 2023 and held it in 6 quarters. The position peaked at $4.7K in Q4 2024. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

  • LGT Financial Advisors reported no remaining Supernus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • LGT Financial Advisors sold 130 Supernus Pharmaceuticals shares in Q1 2025, an estimated $4.7K.
  • LGT Financial Advisors first reported a position in Supernus Pharmaceuticals in Q3 2023 and held it in 6 quarters.
  • LGT Financial Advisors's Supernus Pharmaceuticals position peaked at $4.7K in Q4 2024.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on LGT Financial Advisors's 13F filing for Q1 2025, filed 8 May 2025.